Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial.
dc.contributor.author | Lynch, Maeve | |
dc.contributor.author | Ahern, Tomás B | |
dc.contributor.author | Timoney, Irene | |
dc.contributor.author | Sweeney, Cheryl | |
dc.contributor.author | Kelly, Genevieve | |
dc.contributor.author | Hughes, Rosalind | |
dc.contributor.author | Tobin, Anne-Marie | |
dc.contributor.author | O'Shea, Donal | |
dc.contributor.author | Kirby, Brian | |
dc.date.accessioned | 2017-03-03T12:20:13Z | |
dc.date.available | 2017-03-03T12:20:13Z | |
dc.date.issued | 15/01/2016 | |
dc.identifier.citation | Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial. 2016, 17:29 Trials | en |
dc.identifier.issn | 1745-6215 | |
dc.identifier.pmid | 26767505 | |
dc.identifier.doi | 10.1186/s13063-016-1157-z | |
dc.identifier.uri | http://hdl.handle.net/10147/621122 | |
dc.description.abstract | Moderate to severe psoriasis is a systemic inflammatory disease associated with insulin resistance, obesity and type 2 diabetes (T2DM). Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycaemia and has a marketing authorisation for the treatment of T2DM. Non-immunosuppressive therapies that are effective for psoriasis and its associated comorbidities would be a significant advance in the treatment of this chronic disease. | |
dc.language.iso | en | en |
dc.publisher | BioMed Central Trials | en |
dc.rights | Archived with thanks to Trials | en |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en |
dc.subject | PSORIASIS | en |
dc.subject | SKIN DISORDERS | en |
dc.subject.mesh | Clinical Protocols | |
dc.subject.mesh | Dipeptidyl-Peptidase IV Inhibitors | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Prospective Studies | |
dc.subject.mesh | Psoriasis | |
dc.subject.mesh | Quality Control | |
dc.subject.mesh | Sample Size | |
dc.subject.mesh | Sitagliptin Phosphate | |
dc.subject.mesh | Ultraviolet Therapy | |
dc.title | Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial. | en |
dc.type | Article | en |
dc.identifier.journal | Trials | en |
dc.description.funding | Other | en |
dc.description.province | Leinster | en |
dc.description.peer-review | peer-review | en |
refterms.dateFOA | 2018-08-27T19:46:35Z | |
html.description.abstract | Moderate to severe psoriasis is a systemic inflammatory disease associated with insulin resistance, obesity and type 2 diabetes (T2DM). Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycaemia and has a marketing authorisation for the treatment of T2DM. Non-immunosuppressive therapies that are effective for psoriasis and its associated comorbidities would be a significant advance in the treatment of this chronic disease. |